Medasense is a company specializing in pain management technology. It aims to transform the way pain is assessed and treated worldwide. The company has developed a breakthrough AI technology and sensor platform called NOL® (Nociception Level), which quantifies pain response to optimize care and avoid overmedication. Medasense's flagship product, PMD-200™, is utilized in critical care settings to visualize pain response and personalize treatment. The company also has a pipeline of products that apply its AI capabilities to lead pain prediction, stratification, and prevention strategies. Medasense offers the Medasense Academy, an online and customized education and training program for clinicians and commercial partners. It has a global distribution network, and its products are commercially available in the United States, Europe, Canada, South Africa, UAE, Israel, and select Latin American countries. Medasense is actively involved in industry collaborations and commercial partnerships.